image
Mobile_image
eyebrow
For adults with relapsed or refractory DLBCL
headline

Find your next possibility

content
ADCETRIS, in combination with lenalidomide and rituximab, is approved to treat adults with diffuse large B-cell lymphoma (DLBCL) that has come back (relapsed) or didn’t respond (refractory) after 2 or more prior treatments and who are not candidates for stem cell transplant (HSCT) or CAR-T therapy.

Learn more about the ECHELON-3 study results and ask your doctor if ADCETRIS is an option for you.
buttons
See study results
headline

About relapsed or refractory DLBCL

content
DLBCL is the most common type of non-Hodgkin lymphoma, which is a type of blood cancer. This type of lymphoma starts in early forms of white blood cells called B cells. It typically responds well to initial treatment, yet 30% to 40% of people experience relapsed or refractory DLBCL.

Relapsed DLBCL is when the cancer has returned after signs and symptoms of it had reduced or became undetectable.

Refractory DLBCL is when the cancer does not respond or stopped responding to treatment.
headline

With relapsed or refractory DLBCL, the next step matters

subheadline
Our Treatment Decision Guide can help
content
Use the guide to review the effectiveness of ADCETRIS plus lenalidomide and rituximab, for relapsed or refractory DLBCL.

Get the information you need to help feel confident talking about treatment options with your doctor.
buttons
Download the guide
collection-container
card-grid-container
collection-item-type
core-card, core-text
heading

What is ADCETRIS?

body
ADCETRIS is a targeted treatment called an antibody-drug conjugate. Learn more about how it works.
cta
Discover how ADCETRIS works
heading

How ADCETRIS is given

body
Learn about what you can expect when starting ADCETRIS treatment for relapsed or refractory DLBCL.
cta
Prepare for treatment
heading

Resources and support

body
Find resources, financial assistance information, and ways to connect with others.
cta
Explore ADCETRIS resources
image
Mobile_image
headline

ADCETRIS is a well-established treatment backed by over a decade of clinical data

content
  • Nearly 1700 patients with certain types of lymphoma received treatment with ADCETRIS across 8 clinical trials
  • Over 67,000 patients in the US and over 183,000 patients worldwide have been treated with ADCETRIS since 2011


Healthcare providers have relied on the extensive clinical study data of ADCETRIS when treating their patients. Researchers continue to investigate ADCETRIS in clinical trials today.

collection-container
content-container
collection-container-variant
2-column
collection-item-type
core-content, core-text
headline

Talk to your doctor about ADCETRIS

content
Communicating openly with your doctor is an important part of making sure that your treatment is right for you. Your appointment is an opportunity to share symptoms, ask questions, and discuss your treatment goals. These resources are designed to help you feel confident and prepared to have those conversations with your healthcare provider.
icon
headline

ADCETRIS patient brochure

content

This brochure is intended to help build knowledge and confidence through a detailed overview of ADCETRIS and can help inform treatment discussions with your doctor.

English

Spanish

icon
headline

Doctor Discussion Guide

content

It’s important to ask questions and share concerns about ADCETRIS treatment with a doctor. The Doctor Discussion Guide can help you navigate the conversation, so you get the most out of your visit. Take this printable PDF with you to your next appointment.

View the guide

headline

Glossary

content

CAR-T cell therapy: A cancer treatment in which a type of immune system cell from the patient's blood is changed in the laboratory so they will attack cancer cells.

Stem cell transplant: A procedure in which a patient receives healthy stem cells (blood-forming cells) to replace their own stem cells that have been destroyed by certain cancer treatments.